Regeneron Pharmaceuticals, Inc.
Regeneron Reports Strong Q2 2024 Financial Results with Revenue Growth and Expanded Pipeline
Summary
Regeneron Pharmaceuticals, Inc. announced its second quarter 2024 financial results, showing a 12% increase in total revenues to $3.55 billion. Key products, including Dupixent and EYLEA, saw significant growth in net sales. GAAP diluted EPS increased by 46% to $12.41, while non-GAAP diluted EPS rose by 13% to $11.56. Dupixent received its first regulatory approval for COPD by the European Commission. The company also updated its financial guidance for 2024.
Profitelligence Alerts
Get alerts for REGN
Be first to know when Regeneron Pharmaceuticals, Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. is a biotechnology company focused on the discovery, development, and commercialization of medicines for serious medical conditions. The company's primary function is to address unmet medical needs through innovative treatments derived from its robust pipeline of pharmaceutical products. Regeneron is particularly notable for its contributions to the healthcare industry with products that target ailments such as eye diseases, inflammatory conditions, and cancer. Among its key offerings are EYLEA, an injection for retinal diseases, and Dupixent, used to treat eczema and asthma. Based in Tarrytown, New York, Regeneron employs cutting-edge technologies like its VelociSuite platform, which enhances drug invention capabilities. The company plays a significant role in the biotechnology sector by delivering high-impact therapies that improve patient outcomes. With a strong emphasis on research and development, Regeneron continues to expand its impact across global markets, providing vital solutions to complex health challenges.
Official SEC Documents
Advertisement